Test Price
2,800 AED✅ Home Collection Available
PIEZO2 Gene Marden-Walker Syndrome Genetic Test in UAE | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Precision Genetic Diagnosis for Dysmorphology Syndromes
- Diagnostic Accuracy: 99.9% sensitivity via ISO 9001:2015-accredited next-generation sequencing across all coding exons and splice junctions of the PIEZO2 gene.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection conducted by DHA-licensed practitioners, available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post-test consultation with a consultant medical geneticist to interpret PIEZO2 variant findings and guide family counseling.
- Insurance Enrollment: Direct billing verification and pre-authorization support via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The PIEZO2 gene test utilizes comprehensive next-generation sequencing to interrogate the entire coding region and conserved splice sites, identifying pathogenic and likely pathogenic variants responsible for Marden-Walker syndrome (MWS). This autosomal recessive disorder presents with congenital joint contractures, blepharophimosis, distinctive dysmorphic features, and developmental delay. The NGS-based assay replaces fragmented single-exon Sanger analysis, delivering a definitive molecular diagnosis that informs clinical management, recurrence risk assessment, and reproductive planning for affected families.
| Feature | DNA Labs UAE NGS Test | Traditional Sanger Single-Exon |
|---|---|---|
| Coverage | 100% of coding PIEZO2 exons plus flanking splice regions | Limited to pre-selected hotspots; misses approximately 60% of pathogenic variants |
| Turnaround Time | 21 to 28 days | 42 to 56 days due to multi-step reflex testing |
| Clinical Utility | Definitive molecular diagnosis, carrier detection, and reproductive risk stratification | Probabilistic result often necessitating follow-up NGS confirmation |
Physician Insight & Safety Protocols
"A molecular finding in PIEZO2 must never be interpreted in isolation. The variant pathogenicity classification requires careful correlation with the full dysmorphology assessment, family pedigree, and clinical phenotype by an experienced medical genetics team. Families should understand that a positive result guides surveillance and counseling but does not replace multidisciplinary clinical care."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory
Critical Safety Information
Do not alter, initiate, or discontinue any medication, therapy, or supportive care regimen solely on the basis of this genetic test result. All management decisions must be made in consultation with the treating pediatrician and a qualified clinical geneticist. If the patient develops acute respiratory distress, seizures, or severe feeding intolerance, proceed to the nearest emergency department immediately without waiting for genetic results.
Eligibility & Exclusion Criteria
Exclusion Criteria for Testing
- Informed consent: Inability to obtain written informed consent from a legal guardian, as mandated by Federal Decree-Law No. 4 of 2016 on Medical Liability for genetic testing involving minors.
- Medical contraindication: Active blood-borne infection or severe anemia where venipuncture poses clinical risk; an alternative FTA card collection may be considered after physician approval.
- Sample integrity: Specimen collected outside the validated cold-chain temperature window (2–8°C) will necessitate recollection at no additional charge.
- Incomplete pedigree: Absence of a documented three-generation family pedigree limits variant segregation analysis and may reduce diagnostic yield.
Patient FAQ & Clinical Guidance
1. What is the PIEZO2 gene test and why is it needed?
Answer: This advanced NGS analysis detects pathogenic variants in the PIEZO2 gene associated with Marden-Walker syndrome. It provides a definitive molecular diagnosis for suspected dysmorphology cases, enables accurate genetic counseling, and informs recurrence risk assessment for family planning.
2. How is the sample collected and what is the turnaround time?
Answer: A DHA-licensed phlebotomist performs a home visit to collect a peripheral whole blood sample or a finger-prick FTA card under strict cold-chain protocols. Results are delivered securely via encrypted portal within 21 to 28 days from sample receipt.
3. Is this test covered by insurance and is genetic counseling included?
Answer: Most UAE health insurers cover PIEZO2 genetic testing when medically indicated. Our team verifies coverage and handles pre-authorization via WhatsApp at +971 54 548 8731. A pre-test and post-test genetic counseling session with a consultant medical geneticist is included at no additional cost.
4. What does a positive or negative result mean for my family?
Answer: A positive result identifies a pathogenic variant that confirms the diagnosis and allows carrier testing for parents and at-risk relatives. A negative result reduces but does not eliminate the possibility of MWS; further evaluation by a dysmorphology team may still be warranted based on clinical findings.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This genetic testing service operates in full conformity with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genomic data is encrypted, access-controlled, and processed exclusively within UAE jurisdiction.
Medical Liability Framework: Clinical genetic testing and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that all testing is performed under valid informed consent with clear disclosure of benefits, limitations, and implications.
Clinical & Logistical Metadata
| Test Name | PIEZO2 Gene Marden-Walker Syndrome Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 21 to 28 days |
| Sample Type / Matrix | Peripheral Whole Blood or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Sequencing |
| ICD-10-CM Code | Q87.0 |
| LOINC Code | 94268-2 |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians